en
Scientific article
Open access
English

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Published inAlzheimer's & dementia, vol. 13, no. 3, p. 274-284
Publication date2017
Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

Citation (ISO format)
SIMONSEN, Anja Hviid et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. In: Alzheimer’s & dementia, 2017, vol. 13, n° 3, p. 274–284. doi: 10.1016/j.jalz.2016.09.008
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1552-5260
428views
143downloads

Technical informations

Creation06/08/2017 12:33:00 PM
First validation06/08/2017 12:33:00 PM
Update time03/15/2023 1:46:19 AM
Status update03/15/2023 1:46:17 AM
Last indexation02/12/2024 12:44:35 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack